報價延遲最少15分鐘:2026/03/05 14:15 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.28 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.26/0.56
|
|
企業價值
1.78B
|
| 資產負債 |
|
每股賬面淨值
0.68
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
407.32M
|
|
每股收益
0.55
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. |
